Brain protection by transamniotic stem cell therapy (TRASCET) in a model of intrauterine growth restriction (IUGR).

Autor: Whitlock AE; Department of Surgery, Boston Children's Hospital/ Harvard Medical School, Boston, MA, United States., Moskowitzova K; Department of Surgery, Boston Children's Hospital/ Harvard Medical School, Boston, MA, United States., Labuz DF; Department of Surgery, Boston Children's Hospital/ Harvard Medical School, Boston, MA, United States., Kycia I; Department of Surgery, Boston Children's Hospital/ Harvard Medical School, Boston, MA, United States., Zurakowski D; Department of Surgery, Boston Children's Hospital/ Harvard Medical School, Boston, MA, United States., Fauza DO; Department of Surgery, Boston Children's Hospital/ Harvard Medical School, Boston, MA, United States. Electronic address: dario.fauza@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of pediatric surgery [J Pediatr Surg] 2023 Jan; Vol. 58 (1), pp. 3-7. Date of Electronic Publication: 2022 Oct 17.
DOI: 10.1016/j.jpedsurg.2022.09.018
Abstrakt: Purpose: Transamniotic stem cell therapy (TRASCET) with mesenchymal stem cells (MSCs) has been shown experimentally to reverse some of the effects of intrauterine growth restriction (IUGR), apparently by attenuating placental inflammation. Neurodevelopmental deficits driven by neuroinflammation are major complications of IUGR. We sought to determine whether MSC-based TRASCET also mitigates inflammation in the fetal brain.
Methods: Pregnant Sprague-Dawley dams (n = 8) were exposed to alternating 12-hour hypoxia (10.5% O 2 ) cycles from gestational day 15 (E15) until term (E21). One group remained untreated (n = 28 fetuses). Three groups received volume-matched intra-amniotic injections into all fetuses (n = 72) of either saline (sham; n = 19), or a suspension of amniotic fluid-derived MSCs, either in native state (TRASCET; n = 20), or primed by exposure to interferon-gamma (IFN-γ) and interleukin-1beta (IL-1β) for 24 h prior to administration in vivo (TRASCET-Primed; n = 29). Donor MSCs were syngeneic Lewis rat cells phenotyped by flow cytometry. Normal fetuses served as controls (n = 20). Multiple analyses were performed at term, including ELISA in fetal brains for the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and IL-1β. Statistical comparisons were by Wilcox-rank sum test, including Bonferroni-adjusted significance.
Results: Overall survival was 75% (88/116). Gross brain weights were significantly decreased from normal in both the untreated and sham groups (both p<0.001) and significantly increased in both TRASCET groups when compared to untreated and sham (p = 0.003 to <0.001). TRASCET-Primed led to significantly lower levels of TNF-α and IL-1β compared to untreated (both p<0.001) and sham (p = 0.017 and p = 0.011, respectively). Non-primed TRASCET led to significantly lower levels of TNF-α and IL-1β compared to untreated (p = 0.009 to <0.001), but not sham (p = 0.133 and p = 0.973, respectively).
Conclusions: Transamniotic stem cell therapy with primed mesenchymal stem cells reverses some of the central nervous system effects of intrauterine growth restriction in a rat model, possibly by modulating neuroinflammation.
Type of Study: Animal and laboratory study.
Level of Evidence: N/A (animal and laboratory study).
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: